{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:55:19Z","timestamp":1773518119267,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","award":["62050035"],"award-info":[{"award-number":["62050035"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","award":["62050035"],"award-info":[{"award-number":["62050035"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","award":["62050035"],"award-info":[{"award-number":["62050035"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","award":["62050035"],"award-info":[{"award-number":["62050035"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer Netherlands","doi-asserted-by":"publisher","award":["62050035"],"award-info":[{"award-number":["62050035"]}],"id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10096-025-05339-7","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T11:01:39Z","timestamp":1763031699000},"page":"679-690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A mixed methods approach (EXPANS) to assess current and future uses of antimicrobials: a case study of ceftaroline"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-6764","authenticated-orcid":false,"given":"Hester H.","family":"Stoorvogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies E.J.L.","family":"Hulscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kolwijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.G.","family":"Huis in \u2019t Veld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adar","family":"Zeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen A.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"ten Oever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiman F.L.","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"5339_CR1","volume-title":"And use surveillance system (GLASS) report 2022","author":"Global antimicrobial resistance","year":"2022","unstructured":"Global antimicrobial resistance (2022) And use surveillance system (GLASS) report 2022. World Health Organization, Geneva"},{"key":"5339_CR2","unstructured":"Political Declaration of the High-level Meeting on Antimicrobial Resistance (2024) United Nations General Assembly (UNGA)"},{"key":"5339_CR3","volume-title":"National Ownership of Antibiotic Access and Use","author":"D Mora-Brito","year":"2024","unstructured":"Mora-Brito D, Freeman R, Sharland M, Pillai N, Elepa\u00f1o A, Adam A et al (2024) National Ownership of Antibiotic Access and Use. Driving Policy Decision-Making Based on Population Needs. IQVIA"},{"key":"5339_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1397602","volume":"15","author":"P Glajzner","year":"2024","unstructured":"Glajzner P, Bernat A, Jasi\u0144ska-Stroschein M (2024) Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning. Front Pharmacol 15:1397602","journal-title":"Front Pharmacol"},{"issue":"1","key":"5339_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1298190","volume":"5","author":"G Nayroles","year":"2017","unstructured":"Nayroles G, Frybourg S, Gabriel S, Kornfeld \u00c5, Anto\u00f1anzas-Villar F, Esp\u00edn J et al (2017) Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. J Market Access Health Policy 5(1):1298190","journal-title":"J Market Access Health Policy"},{"issue":"12","key":"5339_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1586\/eri.12.137","volume":"10","author":"GS Tansarli","year":"2012","unstructured":"Tansarli GS, Rafailidis PI, Kapaskelis A, Falagas ME (2012) Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti-Infect Ther 10(12):1383\u20131392","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"4","key":"5339_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2165\/00003495-199753040-00002","volume":"53","author":"R Janknegt","year":"1997","unstructured":"Janknegt R, Steenhoek A (1997) The system of objectified judgement analysis (SOJA). a tool in rational drug selection for formulary inclusion. Drugs 53(4):550\u2013562","journal-title":"Drugs"},{"issue":"49","key":"5339_CR8","first-page":"2466","volume":"143","author":"R Janknegt","year":"1999","unstructured":"Janknegt R, van den Broek PJ, Kullberg BJ, Stobberingh E (1999) [Choice of antibiotics in uncomplicated cystitis; application of \u2018system of objectified judgement analysis\u2019 (SOJA) method]. Ned Tijdschr Geneeskd 143(49):2466\u20132471","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"3","key":"5339_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/tct.13145","volume":"17","author":"A Kajamaa","year":"2020","unstructured":"Kajamaa A, Mattick K, de la Croix A (2020) How to \u2026 do mixed-methods research. Clin Teach 17(3):267\u2013271","journal-title":"Clin Teach"},{"issue":"7","key":"5339_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/bmjqs-2023-016112","volume":"33","author":"TC Guetterman","year":"2024","unstructured":"Guetterman TC, Manojlovich M (2024) Grand rounds in methodology: designing for integration in mixed methods research. BMJ Qual Saf. https:\/\/doi.org\/10.1136\/bmjqs-2023-016112","journal-title":"BMJ Qual Saf"},{"issue":"2","key":"5339_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx084","volume":"4","author":"RA Cosimi","year":"2017","unstructured":"Cosimi RA, Beik N, Kubiak DW, Johnson JA (2017) Ceftaroline for severe Methicillin-resistant Staphylococcus aureus infections: a systematic review. Open Forum Infect Dis 4(2):ofx084","journal-title":"Open Forum Infect Dis"},{"key":"5339_CR12","unstructured":"(EMA) EMA Zinforo - ceftaroline fosamil [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zinforo"},{"issue":"Suppl 3","key":"5339_CR13","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1093\/cid\/cis562","volume":"55","author":"RK Flamm","year":"2012","unstructured":"Flamm RK, Sader HS, Farrell DJ, Jones RN (2012) Ceftaroline potency among 9 US census regions: report from the 2010 AWARE program. Clin Infect Dis 55(Suppl 3):S194-205","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5339_CR14","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/jac\/dkv007","volume":"70","author":"JR Smith","year":"2015","unstructured":"Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ (2015) \u03b2-lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 70(6):1738\u20131743","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5339_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijantimicag.2019.06.025","volume":"54","author":"A Pani","year":"2019","unstructured":"Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D, Scaglione F (2019) Off-label use of Ceftaroline fosamil: a systematic review. Int J Antimicrob Agents 54(5):562\u2013571","journal-title":"Int J Antimicrob Agents"},{"key":"5339_CR16","unstructured":"de Greef SC, Kolwijck E, Schoffelen AF, NethMap (2023) Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2022. Rijksinstituut voor Volksgezondheid en Milieu. Contract No.: 2023\u20130372"},{"issue":"4","key":"5339_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.37201\/req\/143.2022","volume":"36","author":"A Alonso \u00c1lvarez","year":"2023","unstructured":"Alonso \u00c1lvarez A, S\u00e1nchez Vidal E, Ramos Merino L, Sousa Regueiro D, Serrano Areba J, M\u00edguez Rey E (2023) Llinares Mod\u00e9jar P. Use of Ceftaroline in complex central nervous system infections. Rev Esp Quimioter 36(4):434\u2013435","journal-title":"Rev Esp Quimioter"},{"key":"5339_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jgar.2023.01.004","volume":"32","author":"C Bouchand","year":"2023","unstructured":"Bouchand C, Navas D, Corvec S, Pattier S, Roussel JC, Lepoivre T et al (2023) Postoperative linezolid-resistant methicillin-resistant Staphylococcus epidermidis mediastinitis in a heart transplant patient: first case of therapeutic success with Delafloxacin. J Glob Antimicrob Resist 32:72\u201373","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"5339_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/emph\/eoaa031","volume":"2020","author":"NF Brazeau","year":"2020","unstructured":"Brazeau NF, Levinson KJ, Schranz A, Moser KA, Hollis I, Iyer P et al (2020) Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in walk. Evol Med Public Health 2020(1):219\u2013224","journal-title":"Evol Med Public Health"},{"issue":"10","key":"5339_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/INF.0000000000004023","volume":"42","author":"A Callies","year":"2023","unstructured":"Callies A, Martin-Perceval L, Cr\u00e9met L, G\u00e9ly L, Ruellan AL, Verdier MC et al (2023) Safety and efficacy of Ceftaroline in neonates with Staphylococcal late-onset sepsis: a case series analysis. Pediatr Infect Dis J 42(10):888\u2013892","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"5339_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1120700020936628","volume":"32","author":"KH Cichos","year":"2022","unstructured":"Cichos KH, Detweiler M, Parvizi J, McGwin G Jr., Heatherly AR, Ghanem ES (2022) The fate of positive intraoperative cultures following conversion total hip arthroplasty. Hip Int 32(1):17\u201324","journal-title":"Hip Int"},{"issue":"5","key":"5339_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","volume":"53","author":"CJ Destache","year":"2019","unstructured":"Destache CJ, Guervil DJ, Kaye KS (2019) Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents 53(5):644\u2013649","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"5339_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy246","volume":"5","author":"T Ferry","year":"2018","unstructured":"Ferry T, Batailler C, Conrad A, Triffault-Fillit C, Laurent F, Valour F, Chidiac C (2018) Correction of Linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for Multidrug-Resistant Staphylococcus epidermidis prosthetic-joint infection. Open Forum Infect Dis 5(10):ofy246","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"5339_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/ejhpharm-2019-002183","volume":"28","author":"A Gasc\u00f3n","year":"2021","unstructured":"Gasc\u00f3n A, Castresana M, Alzueta N, Marin M, P\u00edo M, Echeverria A (2021) Combination of ceftaroline and daptomycin as treatment for complicated osteomyelitis. Eur J Hosp Pharm 28(5):289\u2013292","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"5339_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106918","volume":"62","author":"C Hidalgo-Tenorio","year":"2023","unstructured":"Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enr\u00edquez-G\u00f3mez A, Mu\u00f1oz P, Plata-Ciezar A, Mir\u00f3 JM et al (2023) EN-DALBACEN 2.0 cohort: real-life study of Dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive Cocci. Int J Antimicrob Agents 62(3):106918","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5339_CR26","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2015.706","volume":"5","author":"M Mehmood","year":"2015","unstructured":"Mehmood M, Khasawneh FA (2015) Staphylococcus lugdunensis gluteal abscess in a patient with end stage renal disease on hemodialysis. Clin Pract 5(1):706","journal-title":"Clin Pract"},{"key":"5339_CR27","doi-asserted-by":"publisher","first-page":"S563","DOI":"10.1093\/ofid\/ofz360.1407","volume":"6","author":"M Murphy","year":"2019","unstructured":"Murphy M, Tang-Girdwood S, Tang P, Rebecca BC, Mizuno T, Vinks A (2019) Ceftaroline model-based dose individualization in an infant with kidney disease and mediastinitis. OFID and Open Forum Infect Dis: IDWeek 6:S563","journal-title":"OFID and Open Forum Infect Dis: IDWeek"},{"key":"5339_CR28","doi-asserted-by":"crossref","unstructured":"Rajendraprasad S, Kenny D, Cruz Torres R, Velagapudi M (2021) Aortic root abscess: a rare complication of Staphylococcus Epidermidis prosthetic valve endocarditis. Chest Conference: CHEST 2021 Annual Meeting 160:A295","DOI":"10.1016\/j.chest.2021.07.301"},{"key":"5339_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.wneu.2020.01.013","volume":"136","author":"A Roujansky","year":"2020","unstructured":"Roujansky A, Martin M, Gomart C, Hulin A, Mounier R (2020) Multidrug-resistant Staphylococcus epidermidis ventriculostomy-related infection successfully treated by intravenous ceftaroline after failure of daptomycin treatment. World Neurosurg 136:221\u2013225","journal-title":"World Neurosurg"},{"issue":"10","key":"5339_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","volume":"36","author":"G Sakoulas","year":"2014","unstructured":"Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY et al (2014) Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 36(10):1317\u20131333","journal-title":"Clin Ther"},{"issue":"7","key":"5339_CR31","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dku085","volume":"69","author":"P Tattevin","year":"2014","unstructured":"Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M et al (2014) Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 69(7):2010\u20132013","journal-title":"J Antimicrob Chemother"},{"key":"5339_CR32","volume":"2017","author":"S Biso","year":"2017","unstructured":"Biso S, Lekkham R, Climaco A (2017) Aspergillus pericarditis with tamponade in a renal transplant patient. Case Rep Cardiol 2017:7134586","journal-title":"Case Rep Cardiol"},{"issue":"9","key":"5339_CR33","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/cid\/ciab832","volume":"74","author":"AM Khatri","year":"2022","unstructured":"Khatri AM, Anderson AD, Camargo JF (2022) Addition of oral fosfomycin to antimicrobial salvage therapy for persistent vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 74(9):1710\u20131711","journal-title":"Clin Infect Dis"},{"key":"5339_CR34","doi-asserted-by":"crossref","unstructured":"Matute P, Gimenez-Mila M, Ibanez C, Mestres G, Yugueros X, Rovira I (2021) Aortic stenosis in a complex case of major vascular surgery.\u00a0J Cardiothorac Vasc Anesth:EACTAIC-ICCVA 35:S43","DOI":"10.1053\/j.jvca.2021.08.098"},{"issue":"2","key":"5339_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13251","volume":"22","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Gill CM, Kenney RM, Alangaden GJ, Davis SL (2020) Treatment and outcomes of Enterococcus faecium bloodstream infections in solid organ transplant recipients. Transpl Infect Dis 22(2):e13251","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"5339_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40121-019-00261-w","volume":"8","author":"M Peghin","year":"2019","unstructured":"Peghin M, Russo A, Givone F, Ingani M, Graziano E, Bassetti M (2019) Should high-dose daptomycin be an alternative treatment regimen for enterococcal endocarditis? Infect Dis Ther 8(4):695\u2013702","journal-title":"Infect Dis Ther"},{"key":"5339_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2022.e01593","volume":"29","author":"NB Pincus","year":"2022","unstructured":"Pincus NB, Joshi T, Gatesy SWM, Al-Heeti O, Moore WJ, Bachta KER (2022) Breakthrough daptomycin-, linezolid-, vancomycin-resistant Enterococcus faecium bacteremia during protracted daptomycin therapy: a case report. IDCases 29:e01593","journal-title":"IDCases"},{"issue":"5","key":"5339_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106432","volume":"58","author":"A Russo","year":"2021","unstructured":"Russo A, Venditti M (2021) Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp.: a case series. Int J Antimicrob Agents 58(5):106432","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"5339_CR39","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1128\/AAC.02481-12","volume":"57","author":"G Sakoulas","year":"2013","unstructured":"Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F (2013) Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus Ceftaroline. Antimicrob Agents Chemother 57(8):4042\u20134045","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5339_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa180","volume":"7","author":"Z Udaondo","year":"2020","unstructured":"Udaondo Z, Jenjaroenpun P, Wongsurawat T, Meyers E, Anderson C, Lopez J et al (2020) Two cases of Vancomycin-Resistant Enterococcus faecium bacteremia with development of Daptomycin-Resistant phenotype and its detection using Oxford nanopore sequencing. Open Forum Infect Dis 7(6):ofaa180","journal-title":"Open Forum Infect Dis"},{"issue":"e2","key":"5339_CR41","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1136\/ejhpharm-2017-001221","volume":"25","author":"F Al Madfai","year":"2018","unstructured":"Al Madfai F, Zaidi STR, Ming LC, Wanandy T, Patel RP (2018) Physical and chemical stability of Ceftaroline in an elastomeric infusion device. Eur J Hosp Pharm 25(e2):e115\u2013e9","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"5339_CR42","first-page":"432","volume":"19","author":"S Bhattacharya","year":"2015","unstructured":"Bhattacharya S, Parekh S, Dedhiya M (2015) In-use stability of Ceftaroline fosamil in elastomeric home infusion systems and MINI-BAG plus containers. Int J Pharm Compd 19(5):432\u2013436","journal-title":"Int J Pharm Compd"},{"issue":"7","key":"5339_CR43","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1093\/cid\/ciz1076","volume":"71","author":"ML Bianchini","year":"2020","unstructured":"Bianchini ML, Kenney RM, Lentz R, Zervos M, Malhotra M, Davis SL (2020) Discharge delays and costs associated with outpatient parenteral antimicrobial therapy for high-priced antibiotics. Clin Infect Dis 71(7):e88\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"1\u20135","key":"5339_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/10826076.2023.2216750","volume":"46","author":"P de Oliveira Moretto","year":"2023","unstructured":"de Oliveira Moretto P, Carlos G, Barbosa FDS, Garcia CV, Franco de Oliveira T, Mendez ASL (2023) Simultaneous monitoring of Ceftaroline fosamil and its active form Ceftaroline during stability study of commercial sample - a new stabilityindicating HPLC method, drug decomposition in clinical use conditions and degradation products by LC-MS. J Liquid Chromatogr Relat Technol 46(1\u20135):56\u201366","journal-title":"J Liquid Chromatogr Relat Technol"},{"issue":"1","key":"5339_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cid\/cix733","volume":"66","author":"SC Keller","year":"2018","unstructured":"Keller SC, Williams D, Gavgani M, Hirsch D, Adamovich J, Hohl D et al (2018) Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy. Clin Infect Dis 66(1):11\u201319","journal-title":"Clin Infect Dis"},{"issue":"11","key":"5339_CR46","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.clinthera.2015.09.009","volume":"37","author":"CA Ruh","year":"2015","unstructured":"Ruh CA, Parameswaran GI, Wojciechowski AL, Mergenhagen KA (2015) Outcomes and pharmacoeconomic analysis of a home intravenous antibiotic infusion program in veterans. Clin Ther 37(11):2527\u20132535","journal-title":"Clin Ther"},{"issue":"Suppl 2","key":"5339_CR47","first-page":"5","volume":"11","author":"D Segala","year":"2024","unstructured":"Segala D, Barbieri M, Di Nuzzo M, Benazzi M, Bonazza A, Romanini L et al (2024) Clinical, organizational, and Pharmacoeconomic perspectives of Dalbavancin vs standard of care in the infectious disease network. Glob Reg Health Technol Assess 11(Suppl 2):5\u201312","journal-title":"Glob Reg Health Technol Assess"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05339-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T15:02:10Z","timestamp":1773500530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5339"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05339-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Dutch legislation and confirmed by the medical-ethical evaluation boards of all participating hospitals (2022\u201313791), this study was exempted from the Human Subjects Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"HHS, MEJLH, JAS, JtO and HFLW received an unrestricted research grant from Pfizer [62050035]. No other conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}